Ketone monitoring rises
Continuous ketone monitoring is emerging as a complementary tool to CGM—early advocates say it can detect rising ketones sooner and help prevent DKA in high‑risk patients, adding a new metabolic dimension to remote diabetes management []. This could change how analytics flag acute metabolic risk between clinic visits.
Abbott confirmed development of a dual glucose–ketone biowearable and has publicly outlined the device on its product roadmap, while industry reporting shows integration plans with Tandem Diabetes Care, Beta Bionics, Sequel Med Tech and Ypsomed. abbott.mediaroom.com A McGill-led 14‑day pilot (CKM1, ClinicalTrials.gov NCT06420518) enrolled 16 people with type 1 diabetes and completed primary outcomes in February 2025 to compare the SiBio KS1 CKM against capillary ketone meters. clinicaltrials.gov A larger randomized dataset published in JMIR Diabetes on 13 Jan 2026 reported the SiBio KS1 captured β‑hydroxybutyrate dynamics but noted a gradual day‑to‑day decline in BHB readings over 14 days consistent with sensor drift. diabetes.jmir.org An international expert consensus led by Breakthrough T1D and collaborators, published as guidance in The Lancet Diabetes & Endocrinology and announced 10 Dec 2025, lays out clinical scenarios for CKM use in people with T1D at risk of diabetic ketoacidosis. breakthrought1d.org A Diabetes Technology & Therapeutics case report (published online 24 Jul 2025) described a 55‑year‑old man on automated insulin delivery whose Abbott CKM alarm at >1.0 mmol/L prompted cannula replacement and extra insulin, with ketones peaking >3.1 mmol/L and resolving without hospitalization. liebertpub.com Industry commentary and partner announcements explicitly cite plans to route CKM signals into AID and pump ecosystems to generate automated ketone alarms and programmatic interventions. diabetech.info
